MedTrace Logo

Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS

NCT03696485 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2024-04-18

No results posted yet for this study

Summary

Prospective, single center, open label, phase I/IIa escalating dose study. To evaluate the safety and efficacy of escalating doses of SCM-010 in subjects with SPMS.

Conditions

  • Secondary Progressive Multiple Sclerosis (SPMS)

Interventions

BIOLOGICAL

SCM-010

SCM-010 is comprised of adipose derived expanded mesenchymal cells (ADSC), suspended in Plasma-Lyte and intended for intrathecal (IT) administration.

Sponsors & Collaborators

  • Stem Cell Medicine Ltd.

    lead INDUSTRY

Principal Investigators

  • Arnon Karni, Dr. · Tel Aviv Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2025-02-01
Completion
2025-02-01

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03696485 on ClinicalTrials.gov